We as advocates of marijuana law reforms have never been in a better position than we are today to further our cause. We no longer have to speculate about the potential impacts marijuana legalization will have on public health and safety, and other areas of concern. We can now depend on facts and data to further our efforts to end marijuana prohibition.
Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V -- the lowest restriction classification available under federal law. The rescheduling change is only specific to Epidiolex, and does not amend the schedule I status of either whole-plant cannabis of CBD.